Massive $30.1M bet on SAVA (Cassava Sciences) based on Simufilam's superior Alzheimer's trial data showing cognitive improvement far exceeding competitors and placebo. Key risks include regulatory approval uncertainty, trial data replication concerns, and biotech volatility.